Bacterial Delivery To Lungs
Bacterial Delivery To Lungs - Related Videos
02:22
Performing Intratracheal Bacterial Delivery in a Mouse Model
0 Views •
2025
Source: Venuprasad, K., et al. Intra-tracheal Administration of Haemophilus influenzae in Mouse Models to Study Airway Inflammation. J. Vis. Exp. (2016)This video demonstrates the intratracheal delivery of a lung-pathogenic bacterial inoculum into an anesthetized mouse to model lower respiratory tract infection.
08:00
Intubation-mediated Intratracheal (IMIT) Instillation: A Noninvasive, Lung-specific Delivery System
0 Views •
Cited by 34 •
2014
Intubation-mediated intratracheal (IMIT) instillation of reagents is an excellent, noninvasive method for studying respiratory disease, as well as a method for instilling therapeutic reagents directly into the lung. It is a rapid and highly reproducible method which is suitable for preclinical testing.
02:42
Imaging Bacterial Localization and Host Interaction in Human Lung Tissue
0 Views •
2026
Source: Mills, B., et al., Optical Screening of Novel Bacteria-specific Probes on Ex Vivo Human Lung Tissue by Confocal Laser Endomicroscopy. J. Vis. Exp. (2017)This video demonstrates real-time imaging of fluorescently labeled Staphylococcus aureus in suspension and lung tissue using fibered confocal fluorescence microscopy.
03:18
Intrabronchial Delivery: A Technique to Administer an Experimental Agent Selectively Into a Mouse Lung
0 Views •
2023
This video describes an intrabronchial approach to administer an experimental agent selectively into distal right and left lung. In the featured protocol, we will administer bleomycin intrabronchially into a mouse to obtain a better model for pulmonary fibrosis.
07:56
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
0 Views •
Cited by 18 •
2010
For development of RNA interference (RNAi)-based therapies, a novel strategy was developed, transkingdom RNAi (tkRNAi). This technology uses non-pathogenic bacteria to produce and deliver therapeutic short hairpin RNA (shRNA) into target cells. Here, tkRNAi was successfully applied for reversal of classical ABCB1-mediated multidrug resistance (MDR) of cancer cells.
FAQs
Delivering therapeutic cargo near pulmonary tissues may concentrate activity at the intended site while reducing exposure to the rest of the body. This localized strategy is particularly relevant when treatment targets the airways or lung microenvironment. Its effectiveness still depends on where the bacteria distribute, how long they persist, and whether they can release cargo under pulmonary conditions.
Several factors shape performance: bacterial survival after administration, localization within pulmonary tissues, and the presence of a mechanism that releases the therapeutic molecule, genetic material, or other cargo. These features must function together. A carrier that reaches the lungs but fails to persist or release its payload appropriately may provide limited therapeutic value.
The respiratory system can respond to introduced bacteria, making immune interactions a central design and safety consideration. Immune activity may influence bacterial survival, localization, and clearance, thereby changing how much cargo reaches pulmonary tissues. Development therefore requires balancing delivery performance with control of bacterial safety and the body's response to the carrier.
Distribution determines which regions of the respiratory system receive the carrier, while clearance limits how long it remains available to deliver cargo. Together, these processes influence exposure within the lung microenvironment and the consistency of treatment. Studying both is essential for interpreting delivery outcomes and for assessing whether localized administration produces the intended pulmonary effect.
Administration planning must address the route, the bacterial preparation, the intended pulmonary target, and the cargo-release behavior. Inhalation is identified as a typical localized route, but successful delivery also requires evaluation of bacterial safety, distribution, immune responses, and clearance. These considerations help researchers determine whether the system reaches the lungs in a controlled and useful manner.
The approach may be studied for several pulmonary objectives, including treatment of infections, cancer therapy, vaccination, and gene delivery. In each case, bacteria serve as localized carriers for a relevant biological payload or therapeutic function. The research question determines which outcomes matter most, such as pulmonary localization, cargo release, immune response, safety, or clearance.
Studies should examine whether the bacteria reach and remain in the intended pulmonary tissues, whether they release their cargo, and how the respiratory system responds. Researchers also need to monitor distribution, clearance, and bacterial safety. These measurements connect delivery behavior with therapeutic potential and help identify limitations that could affect consistency or clinical relevance.
For pulmonary infections, localized bacterial carriers could be investigated as a way to deliver biological cargo within the affected respiratory environment. In cancer research, the same principle could support delivery directed toward lung tissues or tumors. Both applications require evidence that the bacteria can localize appropriately, release cargo, and remain sufficiently controlled to limit safety concerns.